慢性乙型肝炎e抗原阴性患者的纤维化进展，间隔10年

StephenW

Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10‐year interval
Lung‐Yi Mak
Wai‐Kay Seto
Rex Wan‐Hin Hui
James Fung
Danny Ka‐Ho Wong
Ching‐Lung Lai
Man‐Fung Yuen
First published: 21 March 2019
Https://doi.org/10.1111/jvh.13095

Funding information:

This study was supported by the SK Yee Medical Foundation (ref no: 2151210) and the Hong Kong Association for the Study of Liver Dieases Young Investigator Research Grant 2015.

Sections

ePDFPDF
Tools
Share
Summary

The study of to influence the evolution of liver fibrosis in CHB across a 10‐year Period. CHB patients with liver stiffness measurement (LSM) by transient elastography 10 years ago were recruited for follow‐up LSM. Fibrosis progression/regression was arbitrarily defined as ≥1 fibrosis stage change from Baseline. A total of 459 hepatitis B e antigen (HBeAg)-negative patients (224 untreated, 235 treated with nucleos(t)ide analogues [NAs]) were recruited. The mean age at baseline LSM was 41.7 ± 9.0 years (56.2% Over 10 years, the proportion of patients with advanced fibrosis/cirrhosis significantly reduced from 16.3% to 5.7% (P < 0.001). Fibrosis progression and regression were observed in 8.7% and 37.5%, respectiv Ely. No treatment with NAs (OR 2.259, 95% confidence interval [CI]: 1.032‐4.945), metabolic syndrome (OR 4.379, 95% CI: 1.128‐16.999) and hepatic steatosis (OR 7.799, 95% CI: 2.271‐ 26.776) was associated with fibrosis progression. Liver stiffness decline artwork positive correlation with the time after HBsAg seroclearance (r = −0.50, P < 0.001). Median liver stiffness was higher both at baseline (14.0 vs 6 kPa, P < 0.001) and 10 years (9.1 vs 4.9 kPa, P < 0.001) in patients with cirrhosis‐related complications/hepatocellular carcinoma compared with those without. In conclusion, CHB‐related liver fibrosis changed dynamically across 10 years. Metabolic syndrome and hepatic steatosis were associated with fibrosis Progression, while antiviral therapy was associated with fibrosis regression. Patients with HBsAg seroclearance demonstrat time-dependent decline in liver stiffness.

StephenW

慢性乙型肝炎e抗原阴性患者的纤维化进展，间隔10年
龙益麦
Wai-Kay Seto
Rex Wan-Hin Hui
詹姆斯冯
Danny Ka-Ho Wong
黎庆龙
万凤媛
首次发表：2019年3月21日
Https://doi.org/10.1111/jvh.13095

资金信息：

本研究得到了SK Yee医学基金会（编号：2151210）和香港肝病研究协会青年研究者研究资助2015的支持。

第

ePDFPDF
工具
分享
摘要

影响CHB肝纤维化进程10年的研究。 10年前通过瞬时弹性成像测量肝脏硬度测量（LSM）的CHB患者被招募用于随访LSM。纤维化进展/消退被任意定义为≥1纤维化阶段从基线变化。招募了总共459名乙型肝炎e抗原（HBeAg）阴性患者（224名未治疗患者，235名患有核苷（t）ide类似物[NAs]）。基线LSM的平均年龄为41.7±9。9年（56.2％，10年内，晚期纤维化/肝硬化患者的比例从16.3％显着降低至5.7％（P <0.001）。纤维化进展和消退的发生率为8.7％和37.5％，相应的Ely。没有NAs治疗（OR 2.259,95％置信区间[CI]：1.032-4.945），代谢综合征（OR 4.379,95％CI：1.128-16.999）和肝脂肪变性（OR 7.799,95 ％CI：2.271-26.776）与纤维化进展相关。肝硬度下降与HBsAg血清清除后的时间呈正相关（r = -0.50，P <0.001）。基线中位肝硬度均较高（14.0 vs 6 kPa，与没有肝硬化相关并发症/肝细胞癌的患者相比，肝硬化相关并发症/肝细胞癌患者的P <0.001）和10年（9.1 vs 4.9 kPa，P <0.001）。总之，CHB相关的肝纤维化在10年内发生了动态变化。代谢综合征和肝脏脂肪变性与纤维化P有关虽然抗病毒治疗与纤维化退行有关，但是进展缓慢。 HBsAg血清清除的患者表现出肝硬度的时间依赖性下降。

StephenW

https://onlinelibrary.wiley.com/doi/full/10.1111/jvh.13095